Light Mode
$0.5645 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.5645, $0.0293 below the day’s high of $0.5938
-0.17 (-23.41%) / 6M
Momentum, market sentiment, and recent alerts
SCNI reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -61.3%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.